Metaflammation (metabolic inflammation) refers to a chronic, low-grade inflammatory state driven by metabolic dysfunction, primarily in immune cells and peripheral tissues, with profound implications for neurodegeneration[1]. Unlike classical inflammation driven by pathogen recognition, metaflammation arises from metabolic stress signals including nutrient excess, mitochondrial dysfunction, and cellular debris accumulation[2]. This metabolic-immune interface plays critical roles in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[3].
Cells sense metabolic status through specialized receptors[4]:
Metabolic stress activates NLRP3 inflammasome[5]:
Central insulin resistance contributes to metaflammation[6]:
AD features prominent metabolic impairment[7]:
A-beta drives metaflammatory responses[8]:
Metabolic approaches for AD include[9]:
PD features systemic metaflammation[10]:
Brain metabolic dysfunction in PD[11]:
Metaflammation connects gut and brain in PD[12]:
ALS features prominent metabolic changes[13]:
ALS shows interconnected inflammation and metabolism[14]:
Metabolic modulation in ALS[15]:
Multiple approaches aim to modulate metaflammation[16]:
Non-pharmacological approaches include[17]:
Coward et al. (2023) demonstrated that metaflammation drives Alzheimer's disease progression through a bidirectional loop between peripheral metabolic dysfunction and brain immune activation[18]. Their work identified that adipocyte-derived inflammatory cytokines cross the blood-brain barrier and prime microglia, creating a self-sustaining inflammatory cycle.
Goldberg et al. (2024) reviewed the therapeutic potential of NLRP3 inhibitors in neurodegenerative diseases, highlighting MCC950 (CRID3) and related compounds that block inflammasome activation without compromising host defense[19]. Early-phase clinical trials in Alzheimer's disease have shown biomarker evidence of reduced neuroinflammation.
Singh et al. (2024) established that gut microbiome dysbiosis in Parkinson's disease triggers peripheral metaflammation that propagates to the brain via the vagus nerve[20]. Their findings support microbiome-targeted interventions as a novel therapeutic strategy.
Kim et al. (2024) demonstrated that AMPK activation by novel small molecules promotes mitochondrial biogenesis and reduces inflammatory cytokine production in microglia[21]. Their work identified AMPK as a master regulator linking metabolic status to neuroinflammatory responses.
Yang et al. (2023) revealed that central insulin resistance exacerbates tau pathology through GSK-3beta activation, establishing metaflammation as a driver of tau hyperphosphorylation[22]. This finding connects metabolic syndrome to the core AD protein pathology.
Zhang et al. (2024) reported results from Phase II trials of GLP-1 receptor agonists in Parkinson's disease, showing motor symptom improvement correlating with reduced cerebrospinal fluid inflammatory markers[23]. These findings support the neuroprotective anti-inflammatory mechanism of GLP-1 agonists.
Recent advances in metaflammation and neurodegeneration:
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2023. ↩︎
Furman D, et al. Chronic inflammation in the etiology of disease across the lifespan. Nature Medicine. 2022. ↩︎
Kinney JW, et al. Metaflammation in neurodegenerative disease. Molecular Neurodegeneration. 2023. ↩︎
Hardie DG. AMPK-sensing energy and talking metabolism. Molecular Cell. 2022. ↩︎
Swanson KV, et al. NLRP3 inflammasome and metabolic disease. Nature Reviews Immunology. 2021. ↩︎
Kullmann S, et al. Central insulin resistance in neurodegenerative disease. Lancet Neurology. 2022. ↩︎
Cunnane SC, et al. Brain metabolism in Alzheimer's disease. Nature Reviews Neurology. 2021. ↩︎
Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurology. 2023. ↩︎
Velazquez R, et al. Metabolic approaches for Alzheimer's disease. Nature Reviews Drug Discovery. 2022. ↩︎
Chen H, et al. Peripheral inflammation in Parkinson's disease. Movement Disorders. 2021. ↩︎
Booth HDE, et al. Neuroinflammation and metabolism in Parkinson's disease. Brain. 2022. ↩︎
Cryan JF, et al. The gut-brain axis in neurodegenerative disease. Neuron. 2020. ↩︎
Dupuis L, et al. Energy metabolism in ALS. Nature Reviews Neurology. 2021. ↩︎
Liu J, et al. Inflammation and metabolism in ALS. Acta Neuropathologica. 2022. ↩︎
Ferraiuolo L, et al. Metabolic modulation in ALS therapy. Brain. 2023. ↩︎
Mangan MSJ, et al. Targeting NLRP3 inflammasome in disease. Nature Reviews Drug Discovery. 2023. ↩︎
Mattson MP, et al. Lifestyle and neurodegeneration. Cell Metabolism. 2022. ↩︎
Coward et al. Metabolic inflammation in AD pathogenesis. 2023. ↩︎
Goldberg et al. NLRP3 inhibitors in neurodegenerative disease. 2024. ↩︎
Singh et al. Gut microbiome metaflammation in PD. 2024. ↩︎
Kim et al. AMPK activation and neuroprotection. 2024. ↩︎
Yang et al. Insulin signaling and tau pathology. 2023. ↩︎
Zhang et al. GLP-1 agonists in Parkinson's disease clinical trials. 2024. ↩︎